Difficulties of acromegaly treatment in young patients clinical case

Florescu Alexandru, Grozavu Ilinka, Condrea Adrian, Loghin Andra, Liliana Moisii, Poieata Ioan, Corina Galesanu

Clinical Endocrinologia – Universitatea de Medicină si Farmacie « Gr. T. Popa » Iasi; 2 Clínica Radiologica - Universitatea de Medicină si Farmacie « Gr. T. Popa » Iasi; 3 Clínica I Neurochirurgie – Universitatea de Medicină si Farmacie « Gr. T. Popa » Iasi

The last decade has provided major progress in the development of highly specific and selective pharmacological agents that have facilitated a more aggressive approach to the treatment of patients with acromegaly. Transsphenoidal surgery still appears to be the best option for most of the patients with GH secreting adenomas. In many cases the biochemical cure targets are not reached and the patient needs adjuvant therapy. Alternatives include medical therapy with somatostatin analogues, growth-hormone-receptor antagonists and dopamine agonists. These drugs can be used alone or in combination. Radiation therapy with conventional fractionated photons or radiosurgery with proton beam could also be effective in some cases.

### CB 26 years old

**Iasi (October 2008)**

**Complaints**

- Headache, excessive perspiration, fatigue, acral enlargement of hands and feet

![Image of a person with a medical case]

**Biochemical findings**

- Basal GH - 156.8 µIU/ml (< 34 µIU/ml)
- IGF-1 - 838.4 ng/ml (150 – 350)
- GH during the glucose suppression test - 153.5 µIU/ml (not suppressed)

**Lateral skull X-ray**

- Major enlargement of the pituitary fossa

**Pituitary CT**

- Expansive pituitary tumour

- Ocreotide (Sandostatin LAR 6) 20 mg/28 days

![Image of a skull scan]

**Biochemical findings**

- IGF1 - X 2009 - 677 ng/ml - VIII 2010 - 767 ng/ml
- GH - < 34 µIU/ml

**Transsphenoidal surgery** in August 2011

- (difficult to perform due to severe bleeding and anatomical abnormalities)

**Gamma Knife**

(September 2011)

The patient develops thyrotopp suppency (L-thyroxin 100 mcg/day), hypertension (nebivolol 5 mcg/day, lecoripin 10 mcg/day) and impaired fasting glucose.

**January 2012 – poor clinical status**

- Ocreotide (Sandostatin LAR 6) 20 mg/28 days, 6 months → 30 mg/28 days

**Biochemical findings**

- IGF1 - X 2012 - 631 ng/ml - VI 2013 - 403 ng/ml - I 2014 - 1162 ng/ml

**We decided to start**

- Ocreotide (Sandostatin LAR 6) 40 mg/28 days
- Somavert (Pegvisomant) 10 mg/daily sc

- IGF1 - V 2014 - 493 ng/ml - VII 2014 - 587 ng/ml - XII 2014 - 541 ng/ml

**Conclusions**

The particularity of the case is represented by the age of the patient and by the fact that throughout a relative short period of time he received the latest available therapy in acromegaly.